3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
20
Leukemia, Myeloid, Acute
8
Recurrence
7
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma
3
Thymoma
2
Ovarian Neoplasms
2
Carcinoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Richter's Transformation
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Temozolomide
73
Bevacizumab
58
Radiotherapy
40
Radiosurgery
28
Carboplatin
23
Nivolumab
17
Etoposide
17
Cisplatin
17
pembrolizumab
16
Irinotecan
16
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Cyclophosphamide
14
Carmustine
14
Pemetrexed
13
Topotecan
10
Surgical Procedures, Operative
10
Capecitabine
10
Lapatinib
9
Filgrastim
9
Trastuzumab
8
Thalidomide
8
Sunitinib
8
Paclitaxel
8
Lomustine
8
Aminolevulinic Acid
8
encorafenib
7
binimetinib
7
Vincristine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Brain Neoplasms
×
selinexor
×
Clear all
NCT01986348
2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2
Terminated
76 enrolled
16 charts